{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T12:28:11Z","timestamp":1792931291766,"version":"4.5.0"},"reference-count":285,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"\n Background<\/jats:title>\n Huntington\u2019s disease (HD) is an autosomal dominant neurodegenerative disorder caused by CAG repeat expansion in the huntingtin gene, leading to progressive neuronal dysfunction and neurodegeneration. Although classically defined as a brain-restricted disorder marked by striatal and cortical degeneration, increasing evidence suggests HD as a multisystem disease involving both central and peripheral pathological alterations.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n This review aims to provide an integrated overview of neuronal and non-neuronal mechanisms underlying HD, focusing on systemic alterations that influence disease onset, progression, and clinical variability. This review also aims to connect neuropharmacology with pharmaceutical formulation strategies, particularly emphasizing the therapeutic and drug-delivery challenges and nanotechnology-based solutions.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n A structured literature review was conducted using databases including PubMed, EMBASE, and Scopus. Using the appropriate keywords, original articles, clinical studies, systematic reviews, meta-analyses, and high-quality reviews were selected based on their relevance to HD pathophysiology and therapeutic strategies.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n HD manifests with motor, cognitive, and psychiatric disturbances; however, this review highlights that peripheral immune activation, gut microbiota dysbiosis, and multiorgan pathology are not merely secondary features but interact with neural circuits, contributing to disease heterogeneity and progression. Current therapeutic approaches are largely symptomatic, achieving minimal effectiveness in disease modification due to challenges such as poor blood\u2013brain barrier penetration, limited target selectivity, and inter-individual variability. New strategies, such as nanotechnology-based drug delivery systems, biologics, and gene editing tools, offer advantages and support a deeper understanding of therapeutic limitations and disease mechanisms, yet their translational applicability remains constrained by limited clinical validation, safety concerns, and scalability problems.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Reconceptualizing HD as a multisystem disorder provides a more comprehensive framework for therapeutic development. Integrating central and peripheral disease mechanisms with advances in targeted drug delivery and patient stratification approaches, such as sex differences, hormonal influences, and environmental factors, is essential for translational progress toward personalized therapeutic approaches. Future research should prioritize interdisciplinary approaches to bridge the gap between mechanistic discoveries and effective disease-modifying interventions.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fphar.2026.1794983","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T05:40:46Z","timestamp":1778132446000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["An integrative neuropharmacological review of Huntington\u2019s disease challenges and the role of novel formulations in addressing pharmacological\u2012pharmaceutical limitations"],"prefix":"10.3389","volume":"17","author":[{"given":"Mahmoud A.","family":"Senousy","sequence":"first","affiliation":[{"name":"Department of Biochemistry, Faculty of Pharmacy, Cairo University","place":["Cairo, Egypt"]},{"name":"Department of Biochemistry, Faculty of Pharmacy and Drug Technology, Egyptian Chinese University","place":["Cairo, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya H.","family":"Eid","sequence":"additional","affiliation":[{"name":"Pharmacology and Toxicology Department, Faculty of Pharmacy, Heliopolis University","place":["Cairo, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Bakr","family":"Zaki","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Pharmacy, University of Sadat City","place":["Menoufia, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"A. Abd-Elmawla","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Pharmacy, Cairo University","place":["Cairo, Egypt"]},{"name":"Department of Biochemistry, Faculty of Pharmacy, Ahram Canadian University","place":["6th of October City, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba R.","family":"Ghaiad","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Pharmacy, Cairo University","place":["Cairo, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riham A.","family":"El-Shiekh","sequence":"additional","affiliation":[{"name":"Department of Pharmacognosy, Faculty of Pharmacy, Cairo University","place":["Cairo, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadek","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University","place":["Cairo, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazim O.","family":"Khalifa","sequence":"additional","affiliation":[{"name":"Department of Veterinary Medicine, College of Agriculture and Veterinary Medicine, United Arab Emirates University","place":["Al Ain, United Arab Emirates"]},{"name":"United Arab Emirates University (UAEU) Center for Public Policy and Leadership, United Arab Emirates University","place":["Al Ain, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood-brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol. Disease"},{"key":"B2","first-page":"254","article-title":"Cysteamine in 3-nitropropionic acid model of Huntington\u2019s disease in rats: modulation of mitochondrial function and amino acid pattern","volume":"1","author":"Abd El-Gawad","year":"2009","journal-title":"Int. J. Med. Med. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00210-024-03603-9","article-title":"Unraveling the impact of miRNAs on gouty arthritis: diagnostic significance and therapeutic opportunities","volume":"398","author":"Abdel Mageed","year":"2024","journal-title":"Naunyn-Schmiedeberg's Archives Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/18796397251330144","article-title":"Emerging roles of microglia and neuroinflammation in huntington's disease: from pathophysiology to clinical trials","volume":"14","author":"Abedrabbo","year":"2025","journal-title":"J. Huntingt. Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1002\/adhm.201500885","article-title":"Development of multifunctional magnetic nanoparticles for genetic engineering and tracking of neural stem cells","volume":"5","author":"Adams","year":"2016","journal-title":"Adv. Healthc. Mater"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.3390\/ijms21093240","article-title":"The metformin mechanism on gluconeogenesis and AMPK activation: the metabolite perspective","volume":"21","author":"Agius","year":"2020","journal-title":"Int. Journal Molecular Sciences"},{"key":"B7","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ijbiomac.2020.06.058","article-title":"Self-assembled lactoferrin-conjugated linoleic acid micelles as an orally active targeted nanoplatform for alzheimer's disease","volume":"162","author":"Agwa","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1093\/hmg\/ddv023","article-title":"A Huntingtin-based peptide inhibitor of caspase-6 provides protection from mutant Huntingtin-induced motor and behavioral deficits","volume":"24","author":"Aharony","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"12583","DOI":"10.1021\/acsomega.0c01592","article-title":"Nanocarriers as potential drug delivery candidates for overcoming the blood-brain barrier: challenges and possibilities","volume":"5","author":"Ahlawat","year":"2020","journal-title":"ACS Omega"},{"key":"B10","doi-asserted-by":"publisher","first-page":"102365","DOI":"10.1016\/j.jddst.2021.102365","article-title":"Co-polymer mixed micelles enhanced transdermal transport of lornoxicam: in vitro characterization, and in vivo assessment of anti-inflammatory effect and antinociceptive activity","volume":"62","author":"Ahmed","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1208\/s12249-023-02516-9","article-title":"Ocular drug delivery: a comprehensive review","volume":"24","author":"Ahmed","year":"2023","journal-title":"AAPS PharmSciTech"},{"key":"B12","doi-asserted-by":"publisher","first-page":"107493","DOI":"10.1016\/j.jddst.2025.107493","article-title":"From bench to biology: unraveling the efficiency of novel brijosomes for trans-tympanic drug delivery","volume":"114","author":"Ahmed","year":"","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1746918","DOI":"10.3389\/fphar.2025.1746918","article-title":"Innovative dual-functional hybrid cationic PEGylated proniosomes as a smart nano-platform for boosted vaginal delivery: multi-level in-vitro,, ex-vivo, microbiological, and in-vivo studies","volume":"16","author":"Ahmed","year":"","journal-title":"Front. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1208\/s12249-026-03366-x","article-title":"Engineered novel brijaluronic terpesomes for brain-targeted Quercetin delivery: optimization, Ex Vivo and radiokinetics","volume":"27","author":"Ahmed","year":"2026","journal-title":"AAPS PharmSciTech"},{"key":"B15","doi-asserted-by":"publisher","first-page":"123338","DOI":"10.1016\/j.ijpharm.2023.123338","article-title":"Sonophoresis-assisted transdermal delivery of antimigraine-loaded nanolipomers: radio-tracking, histopathological assessment and in-vivo biodistribution study","volume":"644","author":"Ahmed Tawfik","year":"2023","journal-title":"Int. J. Pharm."},{"key":"B16","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1177\/18796397251344173","article-title":"The role of astrocytes in human huntington's disease pathology","volume":"14","author":"Al-Dalahmah","year":"2025","journal-title":"J. Huntingt. Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"107061","DOI":"10.1016\/j.ejps.2025.107061","article-title":"Intranasal propranolol hydrochloride-loaded PLGA-Lipid hybrid nanoparticles for brain targeting: optimization and biodistribution study by radiobiological evaluation","volume":"208","author":"Albash","year":"2025","journal-title":"Eur. J. Pharm. Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1093\/neuonc\/not052","article-title":"Enhancing drug delivery for boron neutron capture therapy of brain tumors with focused ultrasound","volume":"15","author":"Alkins","year":"2013","journal-title":"Neuro Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"795","DOI":"10.2147\/IJN.S52236","article-title":"Nanoscale drug delivery systems and the blood-brain barrier","volume":"9","author":"Alyautdin","year":"2014","journal-title":"Int. J. Nanomedicine"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.3390\/metabo12121225","article-title":"Alteration of autophagy and glial activity in nilotinib-treated Huntington\u2019s disease patients","volume":"12","author":"Anderson","year":"2022","journal-title":"Metabolites"},{"key":"B21","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ygcen.2012.07.034","article-title":"Molecular events during the induction of neurodegeneration and memory loss in estrogen-deficient rats","volume":"181","author":"Anukulthanakorn","year":"2013","journal-title":"General Comp. Endocrinol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e38744","DOI":"10.7554\/eLife.38744","article-title":"Metformin reverses early cortical network dysfunction and behavior changes in Huntington\u2019s disease","volume":"7","author":"Arnoux","year":"2018","journal-title":"Elife"},{"key":"B23","doi-asserted-by":"publisher","first-page":"104917","DOI":"10.1016\/j.chemphyslip.2020.104917","article-title":"Intranasal delivery of tetrabenazine nanoemulsion via olfactory region for better treatment of hyperkinetic movement associated with huntington's disease: pharmacokinetic and brain delivery study","volume":"230","author":"Arora","year":"2020","journal-title":"Chem. Phys. Lipids"},{"key":"B24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jconrel.2013.04.007","article-title":"Multiple treatments with liposomal doxorubicin and ultrasound-induced disruption of blood-tumor and blood-brain barriers improve outcomes in a rat glioma model","volume":"169","author":"Aryal","year":"2013","journal-title":"J. Control Release"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.2174\/1567201818666210609161301","article-title":"Targeted drug delivery: trends and perspectives","volume":"18","author":"Ashique","year":"2021","journal-title":"Curr. Drug Deliv."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.2217\/NNM.15.94","article-title":"Novel bimodal iron oxide particles for efficient tracking of human neural stem cells in vivo","volume":"10","author":"Aswendt","year":"2015","journal-title":"Nanomedicine (Lond)"},{"key":"B28","volume-title":"Huntington's disease","author":"Bates","year":"2014"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2015.5","article-title":"Huntington disease","volume":"1","author":"Bates","year":"2015","journal-title":"Nat. Reviews Dis. Primers"},{"key":"B30","doi-asserted-by":"publisher","first-page":"931","DOI":"10.3109\/10717544.2014.880860","article-title":"Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of huntington's disease","volume":"22","author":"Bhatt","year":"2015","journal-title":"Drug Deliv."},{"key":"B31","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.jconrel.2020.12.051","article-title":"Insights into kinetics, release, and behavioral effects of brain-targeted hybrid nanoparticles for cholesterol delivery in huntington's disease","volume":"330","author":"Birolini","year":"2021","journal-title":"J. Control Release"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1084\/jem.20080178","article-title":"A novel pathogenic pathway of immune activation detectable before clinical onset in huntington's disease","volume":"205","author":"Bjorkqvist","year":"2008","journal-title":"J. Exp. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1177\/18796397251338207","article-title":"Neuroinflammation in huntington's disease: causes, consequences, and treatment strategies","volume":"14","author":"Blusch","year":"2025","journal-title":"J. Huntingt. Dis."},{"key":"B34","volume-title":"Rare diseases and orphan products: accelerating research and development","author":"Boat","year":"2011"},{"key":"B35","doi-asserted-by":"publisher","first-page":"14275","DOI":"10.1038\/s41598-017-14290-3","article-title":"Myostatin inhibition prevents skeletal muscle pathophysiology in huntington's disease mice","volume":"7","author":"Bondulich","year":"2017","journal-title":"Sci. Rep."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1172\/JCI27607","article-title":"Cystamine and cysteamine increase brain levels of BDNF in huntington disease via HSJ1b and transglutaminase","volume":"116","author":"Borrell-Pag\u00e8s","year":"2006","journal-title":"J. Clinical Investigation"},{"key":"B37","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S0076-6879(06)12016-9","article-title":"Modeling polyglutamine pathogenesis in C. elegans","volume":"412","author":"Brignull","year":"2006","journal-title":"Methods Enzymol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1586\/14737175.2015.1028369","article-title":"Focused ultrasound-mediated drug delivery through the blood-brain barrier","volume":"15","author":"Burgess","year":"2015","journal-title":"Expert Rev. Neurother."},{"key":"B39","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.drudis.2014.03.005","article-title":"Genetics of huntington's disease and related disorders","volume":"19","author":"Burgunder","year":"2014","journal-title":"Drug Discovery Today"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/ODRR.S49198","article-title":"Orphan drugs in development for huntington's disease: challenges and progress","volume":"5","author":"Burgunder","year":"2015","journal-title":"Orphan Drugs Res. Rev."},{"key":"B41","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00418-017-1553-9","article-title":"Serial block-face scanning electron microscopy applied to study the trafficking of 8D3-coated gold nanoparticles at the blood-brain barrier","volume":"148","author":"Cabezon","year":"2017","journal-title":"Histochem Cell Biol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/s0149-2918(96)80017-8","article-title":"Metformin: a new oral biguanide","volume":"18","author":"Campbell","year":"1996","journal-title":"Clin. Therapeutics"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1042986","DOI":"10.3389\/fbioe.2022.1042986","article-title":"The application of nanotechnology in treatment of alzheimer's disease","volume":"10","author":"Cao","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ncl.2009.04.001","article-title":"Huntington disease and other choreas","volume":"27","author":"Cardoso","year":"2009","journal-title":"Neurol. Clin."},{"key":"B45","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1515\/bmc-2014-0024","article-title":"Peptide-based vectors: recent developments","volume":"5","author":"Cerrato","year":"2014","journal-title":"Biomol. Concepts"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s42247-021-00335-x","article-title":"Review on metal nanoparticles as nanocarriers: current challenges and perspectives in drug delivery systems","volume":"5","author":"Chandrakala","year":"2022","journal-title":"Emergent Mater"},{"key":"B47","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.bbi.2014.09.011","article-title":"Plasma inflammatory biomarkers for huntington's disease patients and mouse model","volume":"44","author":"Chang","year":"2015","journal-title":"Brain Behav. Immun."},{"key":"B48","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3390\/ph6020204","article-title":"Elucidating the function of penetratin and a static magnetic field in cellular uptake of magnetic nanoparticles","volume":"6","author":"Chaudhary","year":"2013","journal-title":"Pharm. (Basel)"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1524767","DOI":"10.3389\/fgeed.2025.1524767","article-title":"Emerging applications of gene editing technologies for the development of climate-resilient crops","volume":"7","author":"Chavhan","year":"2025","journal-title":"Front. Genome"},{"key":"B50","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/1750-1326-6-81","article-title":"Dantrolene is neuroprotective in huntington's disease transgenic mouse model","volume":"6","author":"Chen","year":"2011","journal-title":"Mol. Neurodegeneration"},{"key":"B51","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/neuonc\/nos305","article-title":"Comparing routes of delivery for nanoliposomal Irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts","volume":"15","author":"Chen","year":"2013","journal-title":"Neuro Oncol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"5666","DOI":"10.1039\/c4tb00543k","article-title":"Angiopep-pluronic F127-conjugated superparamagnetic iron oxide nanoparticles as nanotheranostic agents for BBB targeting","volume":"2","author":"Chen","year":"2014","journal-title":"J. Mater Chem. B"},{"key":"B53","doi-asserted-by":"publisher","first-page":"658123","DOI":"10.3389\/fneur.2021.658123","article-title":"Pridopidine for the improvement of motor function in patients with huntington's disease: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Neurology"},{"key":"B54","doi-asserted-by":"publisher","first-page":"607","DOI":"10.3390\/molecules29030607","article-title":"A novel quercetin encapsulated glucose modified liposome and its brain-target antioxidative neuroprotection effects","volume":"29","author":"Chen","year":"2024","journal-title":"Molecules"},{"key":"B55","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.1002\/smll.201400654","article-title":"Blood-brain barrier permeable gold nanoparticles: an efficient delivery platform for enhanced malignant glioma therapy and imaging","volume":"10","author":"Cheng","year":"2014","journal-title":"Small"},{"key":"B56","doi-asserted-by":"publisher","first-page":"8654","DOI":"10.3390\/ijms22168654","article-title":"From menopause to Neurodegeneration\u2014molecular basis and potential therapy","volume":"22","author":"Cheng","year":"2021","journal-title":"Int. Journal Molecular Sciences"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.3390\/nu12102946","article-title":"Dietary intake, mediterranean diet adherence and caloric intake in huntington's disease: a review","volume":"12","author":"Christodoulou","year":"2020","journal-title":"Nutrients"},{"key":"B58","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41596-021-00634-x","article-title":"Hyperosmolar blood-brain barrier opening using intra-arterial injection of hyperosmotic mannitol in mice under real-time MRI guidance","volume":"17","author":"Chu","year":"2022","journal-title":"Nat. Protoc."},{"key":"B59","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1615\/critrevneurobiol.v16.i12.90","article-title":"Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases?","volume":"16","author":"Chuang","year":"2004","journal-title":"Crit. Reviews\u2122 Neurobiol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1136\/jnnp-2019-320879","article-title":"Drug repurposing in neurological diseases: an integrated approach to reduce trial and error","volume":"90","author":"Clout","year":"2019","journal-title":"J. Neurology, Neurosurg. & Psychiatry"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.4103\/1673-5374.215245","article-title":"Promises and pitfalls of immune-based strategies for huntington's disease","volume":"12","author":"Colpo","year":"2017","journal-title":"Neural Regen. Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"E762","DOI":"10.1073\/pnas.1715865115","article-title":"Faulty neuronal determination and cell polarization are reverted by modulating HD early phenotypes","volume":"115","author":"Conforti","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B63","doi-asserted-by":"publisher","first-page":"34725","DOI":"10.1021\/acsami.9b12319","article-title":"Selenium nanoparticles as an efficient nanomedicine for the therapy of Huntington\u2019s disease","volume":"11","author":"Cong","year":"2019","journal-title":"ACS Applied Materials & Interfaces"},{"key":"B64","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jconrel.2015.10.013","article-title":"A critical evaluation of drug delivery from ligand modified nanoparticles: confounding small molecule distribution and efficacy in the central nervous system","volume":"220","author":"Cook","year":"2015","journal-title":"J. Control Release"},{"key":"B65","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3390\/brainsci4010202","article-title":"Use of genetically altered stem cells for the treatment of huntington's disease","volume":"4","author":"Crane","year":"2014","journal-title":"Brain Sci."},{"key":"B66","doi-asserted-by":"publisher","first-page":"559","DOI":"10.3389\/fphys.2018.00559","article-title":"Neuro-cardio mechanisms in huntington's disease and other neurodegenerative disorders","volume":"9","author":"Critchley","year":"2018","journal-title":"Front. Physiol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.it.2015.04.007","article-title":"The choreography of neuroinflammation in huntington's disease","volume":"36","author":"Crotti","year":"2015","journal-title":"Trends Immunol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.nrleng.2025.04.001","article-title":"The association between lifestyle factors and mortality in huntington's disease","volume":"40","author":"Cubo","year":"2025","journal-title":"Neurol. Engl. Ed."},{"key":"B69","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3389\/fnins.2015.00277","article-title":"Ionic homeostasis in brain conditioning","volume":"9","author":"Cuomo","year":"2015","journal-title":"Front. Neurosci."},{"key":"B70","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/pharmaceutics10020057","article-title":"Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems","volume":"10","author":"Danaei","year":"2018","journal-title":"Pharmaceutics"},{"key":"B71","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4103\/0019-5545.105522","article-title":"Off label use of lithium in the treatment of huntington's disease: a case series","volume":"55","author":"Danivas","year":"2013","journal-title":"Indian J. Psy."},{"key":"B72","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.3390\/ijms21093103","article-title":"Neural stem cell transplantation for neurodegenerative diseases","volume":"21","author":"De Gioia","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B73","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1021\/acsbiomaterials.8b01196","article-title":"Designed polymer micelle for clearing amyloid protein aggregates via Up-Regulated autophagy","volume":"5","author":"Debnath","year":"2019","journal-title":"ACS Biomater. Sci. Eng."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.3390\/biomedicines13061409","article-title":"Pharmacological and pathological implications of Sigma-1 receptor in neurodegenerative diseases","volume":"13","author":"Drewes","year":"2025","journal-title":"Biomedicines"},{"key":"B75","doi-asserted-by":"publisher","first-page":"603594","DOI":"10.3389\/fimmu.2020.603594","article-title":"Altered gut microbiota related to inflammatory responses in patients with huntington's disease","volume":"11","author":"Du","year":"2020","journal-title":"Front. Immunol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1177\/18796397251331436","article-title":"The glymphatic system in huntington's disease","volume":"14","author":"Duan","year":"2025","journal-title":"J. Huntingt. Dis."},{"key":"B77","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/mds.20756","article-title":"CYTE\u2010I\u2010HD: phase I dose finding and tolerability study of cysteamine (cystagon) in huntington's disease","volume":"21","author":"Dubinsky","year":"2006","journal-title":"Mov. Disorders Official Journal Mov. Disord. Soc."},{"key":"B78","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.nbd.2019.05.009","article-title":"Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor","volume":"129","author":"Eddings","year":"2019","journal-title":"Neurobiol. Disease"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1111\/febs.17102","article-title":"The microbiota-gut-brain axis in huntington's disease: pathogenic mechanisms and therapeutic targets","volume":"292","author":"Ekwudo","year":"2025","journal-title":"FEBS J."},{"key":"B80","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.ijpharm.2017.06.052","article-title":"Polymeric nanoparticles: promising platform for drug delivery","volume":"528","author":"El-Say","year":"2017","journal-title":"Int. J. Pharm."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1767624","DOI":"10.3389\/fphar.2026.1767624","article-title":"Ketoprofen-loaded quatsomes as a smart repurposed antifungal therapy for vaginal infections: formulation, characterization, and microbiological evaluation","volume":"17","author":"Eldeeb","year":"2026","journal-title":"Front. Pharmacol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1208\/s12249-025-03233-1","article-title":"The road to precision nanomedicine: an insight on drug repurposing and advances in nanoformulations for treatment of cancer","volume":"26","author":"Elmahboub","year":"2025","journal-title":"AAPS PharmSciTech"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.2147\/IJN.S403707","article-title":"Self-assembling lecithin-based mixed polymeric micelles for nose to brain delivery of clozapine: in-vivo assessment of drug efficacy via radiobiological evaluation","volume":"18","author":"Elsharkawy","year":"2023","journal-title":"Int. J. Nanomedicine"},{"key":"B84","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1208\/s12249-026-03342-5","article-title":"Harnessing novel tetra-synergistic bilosomes for effective otomycosis management: integrated in-vitro,, microbiological and in-vivo studies","volume":"27","author":"Fahmy","year":"2026","journal-title":"AAPS PharmSciTech"},{"key":"B85","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1080\/02652048.2025.2500542","article-title":"Repurposing linagliptin-loaded novasomes as a neuroprotectant for alzheimer's disease: in-vitro characterisation, statistical optimisation and ex-vivo permeation study","volume":"42","author":"Farag","year":"2025","journal-title":"J. Microencapsul."},{"key":"B86","doi-asserted-by":"publisher","first-page":"146561","DOI":"10.1016\/j.brainres.2019.146561","article-title":"Back to the origins: human brain organoids to investigate neurodegeneration","volume":"1727","author":"Faravelli","year":"2020","journal-title":"Brain Res."},{"key":"B87","doi-asserted-by":"publisher","first-page":"11795735221092517","DOI":"10.1177\/11795735221092517","article-title":"Current and possible future therapeutic options for Huntington\u2019s disease","volume":"14","author":"Ferguson","year":"2022","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"B88","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3233\/JHD-140127","article-title":"Aggression in huntington's disease: a systematic review of rates of aggression and treatment methods","volume":"3","author":"Fisher","year":"2014","journal-title":"J. Huntingt. Disease"},{"key":"B89","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.3390\/molecules23092238","article-title":"Use of polyamidoamine dendrimers in brain diseases","volume":"23","author":"Florendo","year":"2018","journal-title":"Molecules"},{"key":"B90","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s10439-011-0440-0","article-title":"Real-time imaging of perivascular transport of nanoparticles during convection-enhanced delivery in the rat cortex","volume":"40","author":"Foley","year":"2012","journal-title":"Ann. Biomed. Eng."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1166\/jbn.2015.2078","article-title":"Mucoadhesive amphiphilic methacrylic copolymer-functionalized poly(epsilon-caprolactone) nanocapsules for nose-to-brain delivery of olanzapine","volume":"11","author":"Fonseca","year":"2015","journal-title":"J. Biomed. Nanotechnol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/cncr.22450","article-title":"Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in the treatment of cerebral metastasis","volume":"109","author":"Fortin","year":"2007","journal-title":"Cancer"},{"key":"B93","doi-asserted-by":"publisher","first-page":"657","DOI":"10.2147\/NDT.S6430","article-title":"Tetrabenazine: the first approved drug for the treatment of chorea in US patients with huntington disease","volume":"6","author":"Frank","year":"2010","journal-title":"Neuropsychiatric Disease Treatment"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003495-198835010-00001","article-title":"Bevantolol: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris","volume":"35","author":"Frishman","year":"1988","journal-title":"Drugs"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1111\/bcp.15635","article-title":"A proof\u2010of\u2010concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in huntington's disease","volume":"89","author":"Gamez","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"9542","DOI":"10.3390\/ijms21249542","article-title":"Solid lipid curcumin particles protect medium spiny neuronal morphology, and reduce learning and memory deficits in the YAC128 mouse model of Huntington\u2019s disease","volume":"21","author":"Gharaibeh","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1002\/acn3.52120","article-title":"Modifiable factors associated with huntington's disease progression in presymptomatic participants","volume":"11","author":"Gil-Salcedo","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3233\/JHD-120023","article-title":"Cognitive dysfunction in huntington's disease: humans, mouse models and molecular mechanisms","volume":"1","author":"Giralt","year":"2012","journal-title":"J. Huntingt. Dis."},{"key":"B99","doi-asserted-by":"crossref","first-page":"311","DOI":"10.31887\/DCNS.2006.8.3\/fgirardin","article-title":"Membrane transporter proteins: a challenge for CNS drug development","volume":"8","author":"Girardin","year":"2006","journal-title":"Dialogues Clin. Neurosci."},{"key":"B100","doi-asserted-by":"publisher","first-page":"e1153568","DOI":"10.1080\/21688370.2016.1153568","article-title":"Nanoparticle transport across the blood brain barrier","volume":"4","author":"Grabrucker","year":"2016","journal-title":"Tissue Barriers"},{"key":"B101","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1007\/s12035-021-02638-w","article-title":"CRISPR-Cas9-Mediated gene therapy in neurological disorders","volume":"59","author":"Guan","year":"2022","journal-title":"Mol. Neurobiol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/s41573-021-00217-1","article-title":"Exercise mimetics: harnessing the therapeutic effects of physical activity","volume":"20","author":"Gubert","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"B103","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1016\/j.apsb.2020.11.023","article-title":"Evolution of blood-brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies","volume":"11","author":"Han","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"B104","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1080\/10717544.2020.1745328","article-title":"Neuronal mitochondria-targeted therapy for alzheimer's disease by systemic delivery of resveratrol using dual-modified novel biomimetic nanosystems","volume":"27","author":"Han","year":"2020","journal-title":"Drug Deliv."},{"key":"B105","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.bioactmat.2021.06.002","article-title":"Corrigendum to \u201cMacrophage membrane-coated nanocarriers Co-Modified by RVG29 and TPP improve brain neuronal mitochondria-targeting and therapeutic efficacy in Alzheimer's disease mice\u201d [Bboactive materials 6 (2021) 529-542]","volume":"7","author":"Han","year":"2022","journal-title":"Bioact. Mater"},{"key":"B106","doi-asserted-by":"publisher","first-page":"275","DOI":"10.24272\/j.issn.2095-8137.2023.199","article-title":"Large animal models for Huntington\u2019s disease research","volume":"45","author":"Han","year":"2024","journal-title":"Zoological Res."},{"key":"B107","doi-asserted-by":"publisher","first-page":"fcac308","DOI":"10.1093\/braincomms\/fcac308","article-title":"Use it or lose it: gene-environment interactions at the nexus of expanding genes and shrinking brains in huntington's disease and other experience-dependent disorders of ageing","volume":"4","author":"Hannan","year":"2022","journal-title":"Brain Commun."},{"key":"B108","doi-asserted-by":"publisher","first-page":"7352","DOI":"10.3390\/ijms25137352","article-title":"Novel leptin-based therapeutic strategies to limit synaptic dysfunction in alzheimer's disease","volume":"25","author":"Harvey","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B109","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/mdc3.13178","article-title":"Sex differences in huntington's disease: evaluating the enroll\u2010HD database","volume":"8","author":"Hentosh","year":"2021","journal-title":"Mov. Disorders Clinical Practice"},{"key":"B110","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/adma.201403889","article-title":"A multitheragnostic nanobubble system to induce blood-brain barrier disruption with magnetically guided focused ultrasound","volume":"27","author":"Huang","year":"2015","journal-title":"Adv. Mater"},{"key":"B111","doi-asserted-by":"publisher","first-page":"5033","DOI":"10.1021\/acsnano.2c12840","article-title":"Multiscale NIR-II imaging-guided brain-targeted drug delivery using engineered cell membrane nanoformulation for alzheimer's disease therapy","volume":"17","author":"Huang","year":"","journal-title":"ACS Nano"},{"key":"B112","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1021\/acsbiomaterials.3c00146","article-title":"Biomimetic biomembrane encapsulation and targeted delivery of a nitric oxide release platform for therapy of parkinson's disease","volume":"9","author":"Huang","year":"","journal-title":"ACS Biomater. Sci. Eng."},{"key":"B113","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/s0896-6273(00)80573-5","article-title":"Polyglutamine-expanded human huntingtin transgenes induce degeneration of drosophila photoreceptor neurons","volume":"21","author":"Jackson","year":"1998","journal-title":"Neuron"},{"key":"B114","doi-asserted-by":"publisher","first-page":"9082","DOI":"10.3390\/ijms22169082","article-title":"Nanomedicine for neurodegenerative disorders: focus on alzheimer's and parkinson's diseases","volume":"22","author":"Jagaran","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B115","doi-asserted-by":"publisher","first-page":"104555","DOI":"10.1016\/j.jddst.2023.104555","article-title":"Transferrin functionalized nanostructured lipid carriers for targeting rivastigmine and resveratrol to alzheimer's disease: synthesis, in vitro characterization and brain uptake analysis","volume":"86","author":"Jain","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1080\/14656566.2016.1258063","article-title":"Dopamine depleters in the treatment of hyperkinetic movement disorders","volume":"17","author":"Jankovic","year":"2016","journal-title":"Expert Opinion Pharmacotherapy"},{"key":"B117","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s43556-022-00072-5","article-title":"Enhancing prime editing via inhibition of mismatch repair pathway","volume":"3","author":"Jiang","year":"2022","journal-title":"Mol. Biomed."},{"key":"B118","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s12017-016-8412-z","article-title":"Metformin protects cells from mutant huntingtin toxicity through activation of AMPK and modulation of mitochondrial dynamics","volume":"18","author":"Jin","year":"2016","journal-title":"Neuromolecular Med."},{"key":"B119","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/sj.mp.4000494","article-title":"Anti-bipolar therapy: mechanism of action of lithium","volume":"4","author":"Jope","year":"1999","journal-title":"Mol. Psychiatry"},{"key":"B120","doi-asserted-by":"publisher","first-page":"102607","DOI":"10.1016\/j.jafr.2025.102607","article-title":"From conventional to green extraction of saponins: a review on plant matrices and byproducts","volume":"25","author":"Kamal","year":"2025","journal-title":"J. Agric. Food Res."},{"key":"B121","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/cns.12580","article-title":"Use of PEGylated immunoliposomes to deliver dopamine across the blood-brain barrier in a rat model of parkinson's disease","volume":"22","author":"Kang","year":"2016","journal-title":"CNS Neurosci. Ther."},{"key":"B122","doi-asserted-by":"publisher","first-page":"6240","DOI":"10.3390\/ijms21176240","article-title":"CRISPR-Cas9 DNA base-editing and prime-editing","volume":"21","author":"Kantor","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B123","first-page":"61","article-title":"Development and characterization of in situ gel of embelin for the management of Huntington\u2019s disease","volume":"12","author":"Kapahi","year":"2020","journal-title":"Pharmaspire"},{"key":"B124","doi-asserted-by":"publisher","first-page":"77","DOI":"10.12703\/r\/10-77","article-title":"Huntington\u2019s disease mouse models: unraveling the pathology caused by CAG repeat expansion","volume":"10","author":"Kaye","year":"2021","journal-title":"Fac. Reviews"},{"key":"B125","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3389\/fncel.2017.00216","article-title":"Brain and peripheral atypical inflammatory mediators potentiate neuroinflammation and neurodegeneration","volume":"11","author":"Kempuraj","year":"2017","journal-title":"Front. Cell Neurosci."},{"key":"B126","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jconrel.2018.10.004","article-title":"Recent progress of drug nanoformulations targeting to brain","volume":"291","author":"Khan","year":"2018","journal-title":"J. Control Release"},{"key":"B127","doi-asserted-by":"publisher","first-page":"216206","DOI":"10.1016\/j.ccr.2024.216206","article-title":"Advances in nanotherapeutic strategies for huntington's disease: design, delivery, and neuroprotective mechanisms","volume":"522","author":"Khan","year":"2025","journal-title":"Coord. Chem. Rev."},{"key":"B128","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3233\/JHD-240012","article-title":"Gut microbiota as a modifier of huntington's disease pathogenesis","volume":"13","author":"Khoshnan","year":"2024","journal-title":"J. Huntingt. Dis."},{"key":"B129","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s12078-022-09300-2","article-title":"A nasal aerodynamics perspective of retronasal olfaction: rodents vs. humans","volume":"15","author":"Kim","year":"2022","journal-title":"Chemosens. Percept."},{"key":"B130","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/d41573-021-00088-6","article-title":"Double setback for ASO trials in huntington disease","volume":"20","author":"Kingwell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"B131","doi-asserted-by":"publisher","first-page":"S75","DOI":"10.33549\/physiolres.932566","article-title":"Both water intoxication and osmotic BBB disruption increase brain water content in rats","volume":"62","author":"Kozler","year":"2013","journal-title":"Physiol. Res."},{"key":"B132","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3233\/JHD-160204","article-title":"Therapeutic effects of anthocyanins and environmental enrichment in R6\/1 Huntington\u2019s disease mice","volume":"5","author":"Kreilaus","year":"2016","journal-title":"J. Huntingt. Dis."},{"key":"B133","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s10863-012-9479-3","article-title":"A study of molecular changes relating to energy metabolism and cellular stress in people with huntington's disease: looking for biomarkers","volume":"45","author":"Krzyszton-Russjan","year":"2013","journal-title":"J. Bioenerg. Biomembr."},{"key":"B134","doi-asserted-by":"publisher","first-page":"171","DOI":"10.30574\/gscbps.2021.15.2.0140","article-title":"Huntington\u2019s disease: pathophysiology and therapeutic intervention","volume":"15","author":"Kshirsagar","year":"2021","journal-title":"GSC Biol. Pharm. Sci."},{"key":"B135","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3109\/1061186X.2013.812094","article-title":"Solid lipid nanoparticles carrying chemotherapeutic drug across the blood-brain barrier through insulin receptor-mediated pathway","volume":"21","author":"Kuo","year":"2013","journal-title":"J. Drug Target"},{"key":"B136","doi-asserted-by":"publisher","first-page":"4737","DOI":"10.1172\/JCI64484","article-title":"Mutant huntingtin impairs immune cell migration in huntington disease","volume":"122","author":"Kwan","year":"2012","journal-title":"J. Clin. Invest"},{"key":"B137","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1021\/acsnano.3c09715","article-title":"Mannose-integrated nanoparticle hitchhike glucose transporter 1 recycling to overcome various barriers of oral delivery for alzheimer's disease therapy","volume":"18","author":"Lei","year":"2024","journal-title":"ACS Nano"},{"key":"B138","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1038\/ncomms3753","article-title":"Soluble forms of polyQ-expanded huntingtin rather than large aggregates cause endoplasmic reticulum stress","volume":"4","author":"Leitman","year":"2013","journal-title":"Nat. Communications"},{"key":"B139","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1086\/378133","article-title":"A genome scan for modifiers of age at onset in huntington disease: the HD MAPS study","volume":"73","author":"Li","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"B140","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41586-019-1722-1","article-title":"Allele-selective lowering of mutant HTT protein by HTT-LC3 linker compounds","volume":"575","author":"Li","year":"2019","journal-title":"Nature"},{"key":"B141","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1212\/WNL.0b013e3181ec805b","article-title":"Before chorea: Pre-huntington mild cognitive impairment","volume":"75","author":"Lichter","year":"2010","journal-title":"Neurology"},{"key":"B142","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.3390\/molecules27041372","article-title":"A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives","volume":"27","author":"Liu","year":"2022","journal-title":"Molecules"},{"key":"B143","doi-asserted-by":"publisher","first-page":"833","DOI":"10.4103\/1673-5374.382223","article-title":"Correlation between the gut microbiome and neurodegenerative diseases: a review of metagenomics evidence","volume":"19","author":"Liu","year":"2024","journal-title":"Neural Regen. Res."},{"key":"B144","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41392-024-01743-1","article-title":"Microbiota-gut-brain axis and its therapeutic applications in neurodegenerative diseases","volume":"9","author":"Loh","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"key":"B145","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.colsurfb.2016.04.041","article-title":"Cellular uptake of PLGA nanoparticles targeted with anti-amyloid and anti-transferrin receptor antibodies for alzheimer's disease treatment","volume":"145","author":"Loureiro","year":"2016","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"B146","first-page":"1","article-title":"Zebrafish: a versatile animal model in biomedical research","volume":"6","author":"Madivalar","year":"2024","journal-title":"Int. J. For Multidiscip. Res."},{"key":"B147","first-page":"A166","article-title":"J017 testing metformin against cognitive decline in patients with huntington disease","volume":"95","author":"Maeso","year":"2024","journal-title":"J. Neurology, Neurosurg. and Psychiatry"},{"key":"B148","doi-asserted-by":"publisher","first-page":"13996","DOI":"10.1021\/acs.langmuir.7b02202","article-title":"Trehalose-functionalized gold nanoparticle for inhibiting intracellular protein aggregation","volume":"33","author":"Mandal","year":"2017","journal-title":"Langmuir"},{"key":"B149","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/s0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell"},{"key":"B150","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.4155\/tde.12.80","article-title":"RNAi-based therapies for huntington's disease: delivery challenges and opportunities","volume":"3","author":"Mantha","year":"2012","journal-title":"Ther. Deliv."},{"key":"B151","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1093\/hmg\/ddw050","article-title":"Motor deficits associated with huntington's disease occur in the absence of striatal degeneration in BACHD transgenic mice","volume":"25","author":"Mantovani","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"B152","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1373\/49.10.1726","article-title":"Diagnosis of huntington disease","volume":"49","author":"Margolis","year":"2003","journal-title":"Clin. Chem."},{"key":"B153","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s12668-012-0040-y","article-title":"Amyloid-binding aptamer conjugated Curcumin\u2013PLGA nanoparticle for potential use in alzheimer\u2019s disease","volume":"2","author":"Mathew","year":"2012","journal-title":"BioNanoScience"},{"key":"B154","doi-asserted-by":"publisher","first-page":"528","DOI":"10.3389\/fgene.2020.00528","article-title":"Prime editing: genome editing for rare genetic diseases without double-strand breaks or donor DNA","volume":"11","author":"Matsoukas","year":"2020","journal-title":"Front. Genet."},{"key":"B155","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s43014-020-00044-8","article-title":"A trip of peptides to the brain","volume":"2","author":"Matsui","year":"2020","journal-title":"Food Prod. Process. Nutr."},{"key":"B156","doi-asserted-by":"crossref","DOI":"10.5334\/tohm.394","article-title":"Huntington disease: the complexities of making and disclosing a clinical diagnosis after premanifest genetic testing","volume-title":"Tremor and other hyperkinetic movements","author":"McCusker","year":"2017"},{"key":"B157","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1517\/14728222.11.7.899","article-title":"Enviromimetics: exploring gene environment interactions to identify therapeutic targets for brain disorders","volume":"11","author":"McOmish","year":"2007","journal-title":"Expert Opin. Ther. Targets"},{"key":"B158","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1080\/03007995.2017.1354288","article-title":"A systematic literature review of cysteamine bitartrate in the treatment of nephropathic cystinosis","volume":"33","author":"Medic","year":"2017","journal-title":"Curr. Med. Res. Opin."},{"key":"B159","doi-asserted-by":"publisher","first-page":"325","DOI":"10.20455\/ros.2016.859","article-title":"Huntington's disease-induced cardiac disorders affect multiple cellular pathways","volume":"2","author":"Melkani","year":"2016","journal-title":"React. Oxyg. Species (Apex)"},{"key":"B160","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/cne.10776","article-title":"Time course of early motor and neuropathological anomalies in a knock\u2010in mouse model of huntington","volume":"465","author":"Menalled","year":"2003","journal-title":"Disease 140 CAG Repeats"},{"key":"B161","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.nbd.2009.05.007","article-title":"Systematic behavioral evaluation of huntington's disease transgenic and knock-in mouse models","volume":"35","author":"Menalled","year":"2009","journal-title":"Neurobiol. Disease"},{"key":"B162","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ejpb.2021.11.003","article-title":"Modified cyclodextrin-based nanoparticles mediated delivery of siRNA for huntingtin gene silencing across an in vitro BBB model","volume":"169","author":"Mendon\u00e7a","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"B163","doi-asserted-by":"publisher","first-page":"23247096241278403","DOI":"10.1177\/23247096241278403","article-title":"A challenging diagnosis of huntington\u2019s disease with mild clinical features: case report","volume":"12","author":"Mian","year":"2024","journal-title":"J. Investigative Med. High Impact Case Rep."},{"key":"B164","doi-asserted-by":"publisher","first-page":"e1058464","DOI":"10.1080\/21675511.2015.1058464","article-title":"Huntington's disease is a multi-system disorder","volume":"3","author":"Mielcarek","year":"2015","journal-title":"Rare Dis."},{"key":"B165","doi-asserted-by":"publisher","first-page":"e1004550","DOI":"10.1371\/journal.pgen.1004550","article-title":"Dysfunction of the CNS-Heart axis in mouse models of huntington's disease","volume":"10","author":"Mielcarek","year":"2014","journal-title":"PLoS Genet."},{"key":"B166","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.progpolymsci.2016.09.006","article-title":"Can dendrimer based nanoparticles fight neurodegenerative diseases? Current situation versus other established approaches","volume":"64","author":"Mignani","year":"2017","journal-title":"Prog. Polym. Sci."},{"key":"B167","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.nbd.2006.09.016","article-title":"Cardiac dysfunction in the R6\/2 mouse model of huntington's disease","volume":"25","author":"Mihm","year":"2007","journal-title":"Neurobiol. Disease"},{"key":"B168","doi-asserted-by":"publisher","first-page":"e200159","DOI":"10.1212\/NXG.0000000000200159","article-title":"Adaptive and innate immunity are key drivers of age at onset of multiple sclerosis","volume":"10","author":"Misicka","year":"2024","journal-title":"Neurol. Genet."},{"key":"B169","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.neubiorev.2015.03.003","article-title":"Environmental factors as modulators of neurodegeneration: insights from gene-environment interactions in huntington's disease","volume":"52","author":"Mo","year":"2015","journal-title":"Neurosci. Biobehav Rev."},{"key":"B170","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ymthe.2016.11.010","article-title":"CRISPR\/Cas9 editing of the mutant huntingtin allele in vitro and in vivo","volume":"25","author":"Monteys","year":"2017","journal-title":"Mol. Ther."},{"key":"B171","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/978-1-4939-7825-0_12","article-title":"Large-brained animal models of huntington\u2019s disease: sheep","volume-title":"Huntington\u2019s disease","author":"Morton","year":"2018"},{"key":"B172","doi-asserted-by":"publisher","first-page":"2003054","DOI":"10.1002\/adfm.202003054","article-title":"Recent advancements of nanomedicine in neurodegenerative disorders theranostics","volume":"30","author":"Mukherjee","year":"2020","journal-title":"Adv. Funct. Mater."},{"key":"B173","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s13311-021-01022-9","article-title":"The sigma-1 receptor mediates pridopidine rescue of mitochondrial function in huntington disease models","volume":"18","author":"Naia","year":"2021","journal-title":"Neurotherapeutics"},{"key":"B174","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1085\/jgp.201010551","article-title":"Origins of ion selectivity in potassium channels from the perspective of channel block","volume":"137","author":"Nimigean","year":"2011","journal-title":"J. Gen. Physiol."},{"key":"B175","doi-asserted-by":"publisher","first-page":"117394","DOI":"10.1016\/j.lfs.2020.117394","article-title":"Nanoemulsions for targeting the neurodegenerative diseases: alzheimer's, Parkinson's and Prion's","volume":"245","author":"Nirale","year":"2020","journal-title":"Life Sci."},{"key":"B176","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.3390\/biomedicines11123331","article-title":"Rodent models of huntington's disease: an overview","volume":"11","author":"Nittari","year":"2023","journal-title":"Biomedicines"},{"key":"B177","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s10020-024-00917-5","article-title":"Parthenolide ameliorates 3-nitropropionic acid-induced Huntington\u2019s disease-like aberrations via modulating NLRP3 inflammasome, reducing microglial activation and inducing astrocyte shifting","volume":"30","author":"Noureldeen","year":"2024","journal-title":"Mol. Med."},{"key":"B178","doi-asserted-by":"publisher","first-page":"105725","DOI":"10.1016\/j.nbd.2022.105725","article-title":"Environmental stimulation in huntington disease patients and animal models","volume":"171","author":"Novati","year":"2022","journal-title":"Neurobiol. Disease"},{"key":"B179","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3389\/fnmol.2019.00258","article-title":"The role of microglia and astrocytes in huntington's disease","volume":"12","author":"Palpagama","year":"2019","journal-title":"Front. Mol. Neurosci."},{"key":"B180","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.neuroscience.2006.04.013","article-title":"Differential effects of voluntary physical exercise on behavioral and brain-derived neurotrophic factor expression deficits in huntington's disease transgenic mice","volume":"141","author":"Pang","year":"2006","journal-title":"Neuroscience"},{"key":"B181","doi-asserted-by":"publisher","first-page":"fcac279","DOI":"10.1093\/braincomms\/fcac279","article-title":"Intellectual enrichment and genetic modifiers of cognition and brain volume in huntington's disease","volume":"4","author":"Papoutsi","year":"2022","journal-title":"Brain Commun."},{"key":"B182","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1517\/17425247.2016.1171315","article-title":"CSF, blood-brain barrier, and brain drug delivery","volume":"13","author":"Pardridge","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"B183","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.addr.2011.12.006","article-title":"Polymeric nanoparticles for drug delivery to the central nervous system","volume":"64","author":"Patel","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B184","doi-asserted-by":"publisher","first-page":"1084493","DOI":"10.3389\/fnins.2022.1084493","article-title":"Small molecules to perform big roles: the search for Parkinson's and huntington's disease therapeutics","volume":"16","author":"P\u00e9rez-Arancibia","year":"2023","journal-title":"Front. Neurosci."},{"key":"B185","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/hmg\/ddi004","article-title":"Orexin loss in huntington's disease","volume":"14","author":"Peters\u00e9n","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"B186","doi-asserted-by":"publisher","first-page":"12607","DOI":"10.3390\/ijms241612607","article-title":"Beyond motor deficits: environmental enrichment mitigates huntington's disease effects in YAC128 mice","volume":"24","author":"Placido","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B187","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.nbd.2012.06.026","article-title":"NP03, a novel low-dose lithium formulation, is neuroprotective in the YAC128 mouse model of huntington disease","volume":"48","author":"Pouladi","year":"2012","journal-title":"Neurobiol. Disease"},{"key":"B188","doi-asserted-by":"publisher","first-page":"127938","DOI":"10.1016\/j.molliq.2025.127938","article-title":"Surface-functionalized nanoparticles for targeted drug delivery across the blood-brain barrier: advances and challenges in neurodegenerative disease therapy","volume":"433","author":"Pramoda","year":"2025","journal-title":"J. Mol. Liq."},{"key":"B189","doi-asserted-by":"publisher","first-page":"11455","DOI":"10.1021\/acsnano.2c05795","article-title":"Cholinergic neuron targeting nanosystem delivering hybrid peptide for combinatorial mitochondrial therapy in alzheimer's disease","volume":"16","author":"Qian","year":"2022","journal-title":"ACS Nano"},{"key":"B190","doi-asserted-by":"publisher","first-page":"8525","DOI":"10.1039\/d2tb01499h","article-title":"Aptamer conjugated polydopamine-coated gold nanoparticles as a dual-action nanoplatform targeting beta-amyloid peptide for alzheimer's disease therapy","volume":"10","author":"Qin","year":"2022","journal-title":"J. Mater Chem. B"},{"key":"B191","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s11011-018-0252-0","article-title":"Thymoquinone loaded solid lipid nanoparticles counteracts 3-Nitropropionic acid induced motor impairments and neuroinflammation in rat model of huntington's disease","volume":"33","author":"Ramachandran","year":"2018","journal-title":"Metab. Brain Dis."},{"key":"B192","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1093\/ilar.48.4.356","article-title":"Animal models of huntington's disease","volume":"48","author":"Ramaswamy","year":"2007","journal-title":"Animal Models Huntingt. Disease"},{"key":"B193","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","article-title":"Huntington\u2019s disease: from molecular pathogenesis to clinical treatment","volume":"10","author":"Ross","year":"2011","journal-title":"Lancet Neurol."},{"key":"B194","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1093\/brain\/awac086","article-title":"Translating cell therapies for neurodegenerative diseases: huntington\u2019s disease as a model disorder","volume":"145","author":"Rosser","year":"2022","journal-title":"Brain"},{"key":"B195","doi-asserted-by":"publisher","first-page":"1223911","DOI":"10.3389\/fnagi.2023.1223911","article-title":"Rapamycin reduces neuronal mutant huntingtin aggregation and ameliorates locomotor performance in drosophila","volume":"15","author":"Roth","year":"2023","journal-title":"Front. Aging Neurosci."},{"key":"B196","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/bpa.12426","article-title":"Huntington's disease (HD): the neuropathology of a multisystem neurodegenerative disorder of the human brain","volume":"26","author":"Rub","year":"2016","journal-title":"Brain Pathol."},{"key":"B197","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.reth.2022.09.001","article-title":"Pathogenesis and potential therapeutic application of stem cells transplantation in huntington's disease","volume":"21","author":"Saha","year":"2022","journal-title":"Regen. Ther."},{"key":"B198","doi-asserted-by":"publisher","first-page":"522","DOI":"10.2174\/1871527317666180627103337","article-title":"Effects of the dopamine stabilizer, pridopidine, on basal and phencyclidine-induced locomotion: role of dopamine D2 and sigma-1 receptors","volume":"17","author":"Sahlholm","year":"2018","journal-title":"CNS & Neurological Disorders-Drug Targets"},{"key":"B199","doi-asserted-by":"crossref","DOI":"10.1007\/s00210-025-04444-w","article-title":"Natural products proposed for the management of Huntington's disease (HD): a comprehensive review","author":"Salman","year":"2025","journal-title":"Naunyn Schmiedeb. Arch. Pharmacol."},{"key":"B200","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0264-9","article-title":"Metformin treatment reduces motor and neuropsychiatric phenotypes in the zQ175 mouse model of huntington disease","volume":"51","author":"Sanchis","year":"2019","journal-title":"Exp. and Mol. Med."},{"key":"B201","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s12017-013-8261-y","article-title":"Curcumin nanoparticles attenuate neurochemical and neurobehavioral deficits in experimental model of Huntington\u2019s disease","volume":"16","author":"Sandhir","year":"2014","journal-title":"Neuromolecular Medicine"},{"key":"B202","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/cdd.2008.110","article-title":"Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies","volume":"16","author":"Sarkar","year":"2009","journal-title":"Cell Death & Differ."},{"key":"B203","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.3390\/pharmaceutics13081183","article-title":"Solid lipid nanoparticles (SLNs): an advanced drug delivery system targeting brain through BBB","volume":"13","author":"Satapathy","year":"2021","journal-title":"Pharmaceutics"},{"key":"B204","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/hmg\/8.5.813","article-title":"Formation of polyglutamine inclusions in non-CNS tissue","volume":"8","author":"Sathasivam","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"B205","doi-asserted-by":"publisher","first-page":"102119","DOI":"10.1016\/j.nano.2019.102119","article-title":"Enriched chitosan nanoparticles loaded with siRNA are effective in lowering huntington's disease gene expression following intranasal administration","volume":"24","author":"Sava","year":"2020","journal-title":"Nanomedicine"},{"key":"B206","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1080\/10717544.2021.1951895","article-title":"Brain targeting efficiency of intranasal clozapine-loaded mixed micelles following radio labeling with Technetium-99m","volume":"28","author":"Sayed","year":"2021","journal-title":"Drug Deliv."},{"key":"B207","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10067-024-07291-x","article-title":"New insights into the interplay between MALAT1 and miRNA-155 to unravel potential diagnostic and prognostic biomarkers of Beh\u00e7et\u2019s disease","volume":"44","author":"Sayed","year":"2025","journal-title":"Clin. Rheumatol."},{"key":"B208","doi-asserted-by":"crossref","DOI":"10.1007\/s13346-026-02103-y","article-title":"Advanced modafinil-loaded transethosomes for brain targeting: development, Ex-vivo permeation and radio-distribution evaluations","author":"Sayyed","year":"2026","journal-title":"Drug Deliv. Transl. Res."},{"key":"B209","doi-asserted-by":"publisher","first-page":"25","DOI":"10.37662\/jpt.2020.4","article-title":"Brain-targeted nanoparticles to overcome the blood-brain barrier","volume":"1","author":"Seko","year":"2020","journal-title":"J. Pharm. Technol."},{"key":"B210","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/sj.mp.4001463","article-title":"Short-term lithium treatment promotes neuronal survival and proliferation in rat striatum infused with quinolinic acid, an excitotoxic model of huntington's disease","volume":"9","author":"Senatorov","year":"2004","journal-title":"Mol. Psychiatry"},{"key":"B211","doi-asserted-by":"publisher","first-page":"107318","DOI":"10.1016\/j.jddst.2025.107318","article-title":"Nanotechnology-driven approaches for the management of huntington's disease","volume":"113","author":"Shahrukh","year":"2025","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"B212","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2013.01.016","article-title":"Cell penetrating peptide tethered bi-ligand liposomes for delivery to brain in vivo: biodistribution and transfection","volume":"167","author":"Sharma","year":"2013","journal-title":"J. Control Release"},{"key":"B213","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.ijpharm.2019.01.056","article-title":"Advances in nanocarriers enabled brain targeted drug delivery across blood brain barrier","volume":"559","author":"Sharma","year":"2019","journal-title":"Int. J. Pharm."},{"key":"B214","doi-asserted-by":"publisher","first-page":"604000","DOI":"10.3389\/fimmu.2020.604000","article-title":"Sexual dimorphism in innate immunity: the role of sex hormones and epigenetics","volume":"11","author":"Shepherd","year":"2021","journal-title":"Front. Immunology"},{"key":"B215","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.3390\/pharmaceutics14112425","article-title":"Protein and gene delivery systems for neurodegenerative disorders: where do we stand today?","volume":"14","author":"Siafaka","year":"2022","journal-title":"Pharmaceutics"},{"key":"B216","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1093\/hmg\/ddg169","article-title":"Selective striatal neuronal loss in a YAC128 mouse model of huntington disease","volume":"12","author":"Slow","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"B217","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12987-020-00196-2","article-title":"Choroid plexus and the blood-cerebrospinal fluid barrier in disease","volume":"17","author":"Solar","year":"2020","journal-title":"Fluids Barriers CNS"},{"key":"B218","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1021\/nn4058215","article-title":"Lipoprotein-based nanoparticles rescue the memory loss of mice with alzheimer's disease by accelerating the clearance of amyloid-beta","volume":"8","author":"Song","year":"2014","journal-title":"ACS Nano"},{"key":"B219","doi-asserted-by":"publisher","first-page":"13589","DOI":"10.1523\/JNEUROSCI.4286-09.2009","article-title":"Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of huntington's disease","volume":"29","author":"Southwell","year":"2009","journal-title":"J. Neurosci. The Official Journal Soc. Neurosci."},{"key":"B220","doi-asserted-by":"publisher","first-page":"15729","DOI":"10.1038\/s41598-024-64105-5","article-title":"Sex contribution to average age at onset of Huntington\u2019s disease depends on the number of (CAG) n repeats","volume":"14","author":"Stanis\u0142awska-Sachadyn","year":"2024","journal-title":"Sci. Rep."},{"key":"B221","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1093\/hmg\/ddi192","article-title":"Gene expression in huntington's disease skeletal muscle: a potential biomarker","volume":"14","author":"Strand","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"B222","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.brainres.2018.03.015","article-title":"Neurotransmitter modulation by the gut microbiota","volume":"1693","author":"Strandwitz","year":"2018","journal-title":"Brain Res."},{"key":"B223","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1006\/nbdi.2002.0554","article-title":"Differential changes in striatal projection neurons in R6\/2 transgenic mice for huntington's disease","volume":"11","author":"Sun","year":"2002","journal-title":"Neurobiol. Dis."},{"key":"B224","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.2147\/IJN.S62260","article-title":"Magnetic field enhanced convective diffusion of iron oxide nanoparticles in an osmotically disrupted cell culture model of the blood-brain barrier","volume":"9","author":"Sun","year":"2014","journal-title":"Int. J. Nanomedicine"},{"key":"B225","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1021\/acsnano.2c09752","article-title":"An antisense oligonucleotide-loaded blood-brain barrier penetrable nanoparticle mediating recruitment of endogenous neural stem cells for the treatment of parkinson's disease","volume":"17","author":"Sun","year":"2023","journal-title":"ACS Nano"},{"key":"B226","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1039\/c1cs15238f","article-title":"High-sensitivity nanosensors for biomarker detection","volume":"41","author":"Swierczewska","year":"2012","journal-title":"Chem. Soc. Reviews"},{"key":"B227","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1474-4422(22)00121-1","article-title":"Potential disease-modifying therapies for huntington's disease: lessons learned and future opportunities","volume":"21","author":"Tabrizi","year":"2022","journal-title":"Lancet Neurology"},{"key":"B228","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3233\/JHD-220526","article-title":"Brain alterations in aged OVT73 sheep model of Huntington\u2019s disease: an MRI based approach","volume":"11","author":"Taghian","year":"2022","journal-title":"J. Huntingt. Dis."},{"key":"B229","doi-asserted-by":"publisher","first-page":"100160","DOI":"10.1016\/j.ijpx.2023.100160","article-title":"Cod liver oil nano-structured lipid carriers (Cod-NLCs) as a promising platform for nose to brain delivery: preparation, in vitro optimization, ex vivo cytotoxicity & in vivo biodistribution utilizing radioiodinated zopiclone","author":"Taha","year":"2023","journal-title":"Int. J. Pharm."},{"key":"B230","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s11064-026-04682-1","article-title":"Roflumilast elicits therapeutic and neuroprotective effects in 3-Nitropropionic acid-induced huntington\u2019s disease-like neurodegeneration in rats by mitigating NLRP3 inflammasome-mediated pyroptosis, ferroptosis, and glial activation","volume":"51","author":"Taha","year":"2026","journal-title":"Neurochem. Res."},{"key":"B231","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1093\/brain\/awm044","article-title":"Microglial activation in presymptomatic huntington's disease gene carriers","volume":"130","author":"Tai","year":"2007","journal-title":"Brain"},{"key":"B232","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jconrel.2017.08.033","article-title":"Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases","volume":"264","author":"Tapeinos","year":"2017","journal-title":"J. Control Release"},{"key":"B233","doi-asserted-by":"crossref","DOI":"10.1007\/s13346-023-01373-0","article-title":"Brain targeting of zolmitriptan via transdermal terpesomes: statistical optimization and in vivo biodistribution study by (99m)Tc radiolabeling technique","author":"Tawfik","year":"2023","journal-title":"Drug Deliv. Transl. Res."},{"key":"B234","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1208\/s12249-025-03250-0","article-title":"Oleic acid enriched leciplexes as novel mucoadhesive cationic nanocarriers of agomelatine for glaucoma treatment","volume":"27","author":"Tawfik","year":"2025","journal-title":"AAPS PharmSciTech"},{"key":"B235","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1007\/s12668-025-02105-z","article-title":"Polymeric micelles for pulmonary drug delivery: a comprehensive review","volume":"15","author":"Teama","year":"2025","journal-title":"BioNanoScience"},{"key":"B236","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1002\/jcph.1312","article-title":"Clinical pharmacokinetic and pharmacodynamic overview of nilotinib, a selective tyrosine kinase inhibitor","volume":"58","author":"Tian","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"B237","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.3390\/ijms25073845","article-title":"Huntington's disease: complex pathogenesis and therapeutic strategies","volume":"25","author":"Tong","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B238","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1093\/brain\/awt355","article-title":"HTT-Lowering reverses huntington's disease immune dysfunction caused by NFkappaB pathway dysregulation","volume":"137","author":"Trager","year":"2014","journal-title":"Brain"},{"key":"B239","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1002\/mds.23108","article-title":"A retrospective study of the impact of lifestyle on age at onset of huntington disease","volume":"25","author":"Trembath","year":"2010","journal-title":"Mov. Disord."},{"key":"B240","article-title":"Exploring the role of deutetrabenazine in the treatment of chorea linked with huntington's disease","volume-title":"Current reviews in clinical and experimental pharmacology","author":"Tripathi","year":"2024"},{"key":"B241","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10519-012-9571-9","article-title":"Prenatal rapamycin results in early and late behavioral abnormalities in wildtype C57BL\/6 mice","volume":"43","author":"Tsai","year":"2013","journal-title":"Behav. Genetics"},{"key":"B242","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s10014-016-0255-7","article-title":"Blood-brain barrier and blood-cerebrospinal fluid barrier in normal and pathological conditions","volume":"33","author":"Ueno","year":"2016","journal-title":"Brain Tumor Pathol."},{"key":"B243","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1080\/17460441.2023.2201493","article-title":"Animal models of Huntington\u2019s disease and their applicability to novel drug discovery and development","volume":"18","author":"Upadhayay","year":"2023","journal-title":"Expert Opin. Drug Discov."},{"key":"B244","doi-asserted-by":"publisher","first-page":"869269","DOI":"10.1155\/2014\/869269","article-title":"Drug delivery systems, CNS protection, and the blood brain barrier","volume":"2014","author":"Upadhyay","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"B245","doi-asserted-by":"publisher","first-page":"124866","DOI":"10.1016\/j.ijpharm.2024.124866","article-title":"Advancement in the nose-to-brain drug delivery of FDA-Approved drugs for the better management of depression and psychiatric disorders","volume":"667","author":"Upadhyay","year":"2024","journal-title":"Int. J. Pharm."},{"key":"B246","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/18796397251336192","article-title":"Dysregulated astrocyte cholesterol synthesis in huntington's disease: a potential intersection with other cellular dysfunctions","volume":"14","author":"Valenza","year":"2025","journal-title":"J. Huntingt. Dis."},{"key":"B247","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/35008142","article-title":"Delaying the onset of Huntington's in mice","volume":"404","author":"van Dellen","year":"2000","journal-title":"Nature"},{"key":"B248","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S1474-4422(09)70178-4","article-title":"Beyond the brain: widespread pathology in huntington's disease","volume":"8","author":"van der Burg","year":"2009","journal-title":"Lancet Neurol."},{"key":"B249","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2011.05.006","article-title":"Gastrointestinal dysfunction contributes to weight loss in huntington's disease mice","volume":"44","author":"van der Burg","year":"2011","journal-title":"Neurobiol. Disease"},{"key":"B250","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1093\/hmg\/ddi407","article-title":"Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of huntington disease","volume":"14","author":"Van Raamsdonk","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"B251","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/scrt41","article-title":"Differential fate and functional outcome of lithium chloride primed adult neural progenitor cell transplants in a rat model of huntington disease","volume":"1","author":"Vazey","year":"2010","journal-title":"Stem Cell Research & Therapy"},{"key":"B252","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.arcmed.2014.11.020","article-title":"Cyclodextrins, blood-brain barrier, and treatment of neurological diseases","volume":"45","author":"Vecsernyes","year":"2014","journal-title":"Arch. Med. Res."},{"key":"B253","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/mds.27010","article-title":"A randomized, double\u2010blind, placebo\u2010controlled trial evaluating cysteamine in huntington's disease","volume":"32","author":"Verny","year":"2017","journal-title":"Mov. Disord."},{"key":"B254","doi-asserted-by":"publisher","first-page":"957","DOI":"10.2174\/1570159X18666201109090824","article-title":"Expanding the arsenal against huntington's disease-herbal drugs and their nanoformulations","volume":"19","author":"Vishwas","year":"2021","journal-title":"Curr. Neuropharmacol."},{"key":"B255","doi-asserted-by":"publisher","first-page":"682712","DOI":"10.1155\/2012\/682712","article-title":"Lessons learned from the transgenic huntington's disease rats","volume":"2012","author":"Vlamings","year":"2012","journal-title":"Neural Plast."},{"key":"B256","doi-asserted-by":"publisher","DOI":"10.1371\/currents.hd.cba6ea74972cf8412a73ce52eb018c1e","article-title":"Is there an association of physical activity with brain volume, behavior, and day-to-day functioning? A cross sectional design in prodromal and early huntington disease","volume":"8","author":"Wallace","year":"2016","journal-title":"PLoS Curr."},{"key":"B257","first-page":"53","volume-title":"Mechanistic target of rapamycin (mTOR) inhibitors pharmacology of immunosuppression","author":"Wang","year":"2022"},{"key":"B258","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1073\/pnas.1524575113","article-title":"Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis","volume":"113","author":"Wang","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B259","doi-asserted-by":"publisher","first-page":"7481","DOI":"10.1039\/c9nr01255a","article-title":"Curcumin-primed exosomes potently ameliorate cognitive function in AD mice by inhibiting hyperphosphorylation of the tau protein through the AKT\/GSK-3beta pathway","volume":"11","author":"Wang","year":"2019","journal-title":"Nanoscale"},{"key":"B260","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2165\/00139709-200625040-00003","article-title":"Management of lithium toxicity","volume":"25","author":"Waring","year":"2006","journal-title":"Toxicol. Reviews"},{"key":"B261","doi-asserted-by":"publisher","first-page":"fcaa110","DOI":"10.1093\/braincomms\/fcaa110","article-title":"Gut dysbiosis in huntington's disease: associations among gut microbiota, cognitive performance and clinical outcomes","volume":"2","author":"Wasser","year":"2020","journal-title":"Brain Commun."},{"key":"B262","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3233\/JHD-140116","article-title":"Novel BAC mouse model of huntington's disease with 225 CAG repeats exhibits an early widespread and stable degenerative phenotype","volume":"4","author":"Wegrzynowicz","year":"2015","journal-title":"J. Huntingt. Dis."},{"key":"B263","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/s0306-4522(01)00311-6","article-title":"Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington\u2019s disease","volume":"106","author":"Wei","year":"2001","journal-title":"Neuroscience"},{"key":"B264","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s12247-014-9183-4","article-title":"Recent in vivo evidences of particle-based delivery of small-interfering RNA (siRNA) into solid tumors","volume":"9","author":"Wen","year":"2014","journal-title":"J. Pharm. Innov."},{"key":"B265","doi-asserted-by":"publisher","first-page":"3498","DOI":"10.1073\/pnas.0308679101","article-title":"Venezuelan kindreds reveal that genetic and environmental factors modulate huntington's disease age of onset","volume":"101","author":"Wexler","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B266","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3390\/jpm11080771","article-title":"The enhanced permeability and retention (EPR) effect: the significance of the concept and methods to enhance its application","volume":"11","author":"Wu","year":"2021","journal-title":"J. Pers. Med."},{"key":"B267","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s13233-013-1029-2","article-title":"Cell-penetrating peptide-modified PLGA nanoparticles for enhanced nose-to-brain macromolecular delivery","volume":"21","author":"Yan","year":"2013","journal-title":"Macromol. Res."},{"key":"B268","first-page":"989","article-title":"A huntingtin knockin pig model recapitulates features of selective neurodegeneration","volume":"173","author":"Yan","year":"2018","journal-title":"Huntingt. Disease"},{"key":"B269","article-title":"Interplay between sex and disease burden in Huntington\u2019s disease: clinical and neuroimaging perspectives","author":"Yao","year":"2024","journal-title":"medRxiv 2024.2010. 2031.24315900"},{"key":"B270","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2174\/157340313805076278","article-title":"Induced pluripotent stem cells and their potential for basic and clinical sciences","volume":"9","author":"Ye","year":"2013","journal-title":"Curr. Cardiol. Rev."},{"key":"B271","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s13238-022-00912-8","article-title":"New pathogenic insights from large animal models of","volume":"13","author":"Yin","year":"2022","journal-title":"Neurodegenerative Diseases"},{"key":"B272","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.jconrel.2020.09.043","article-title":"Lactose-appended beta-cyclodextrin as an effective nanocarrier for brain delivery","volume":"328","author":"Yokoyama","year":"2020","journal-title":"J. Control Release"},{"key":"B273","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3345\/cep.2023.00535","article-title":"Development of orphan drugs for rare diseases","volume":"67","author":"Yoo","year":"2024","journal-title":"Clin. Exp. Pediatr."},{"key":"B274","doi-asserted-by":"publisher","DOI":"10.20517\/and.2024.13","article-title":"Advantages and differences among various animal models of Huntington\u2019s disease","author":"Yu","year":"2024","journal-title":"Ageing Neurodegener. Dis."},{"key":"B275","doi-asserted-by":"publisher","first-page":"305","DOI":"10.4252\/wjsc.v6.i3.305","article-title":"Sox2, a key factor in the regulation of pluripotency and neural differentiation","volume":"6","author":"Zhang","year":"2014","journal-title":"World J. Stem Cells"},{"key":"B276","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.brainres.2006.07.005","article-title":"Blood-brain barrier targeting of BDNF improves motor function in rats with middle cerebral artery occlusion","volume":"1111","author":"Zhang","year":"2006","journal-title":"Brain Res."},{"key":"B277","doi-asserted-by":"publisher","first-page":"e1705694","DOI":"10.1002\/adma.201705694","article-title":"Nanomaterials in neural-stem-cell-mediated regenerative medicine: imaging and treatment of neurological diseases","volume":"30","author":"Zhang","year":"2018","journal-title":"Adv. Mater"},{"key":"B278","doi-asserted-by":"publisher","first-page":"114827","DOI":"10.1016\/j.addr.2023.114827","article-title":"Myeloid cell-mediated drug delivery: from nanomedicine to cell therapy","volume":"197","author":"Zhang","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B279","doi-asserted-by":"publisher","first-page":"100034","DOI":"10.1016\/j.sintl.2020.100034","article-title":"Recent development of nucleic acid nanosensors to detect sequence-specific binding interactions: from metal ions, small molecules to proteins and pathogens","volume":"1","author":"Zheng","year":"2020","journal-title":"Sens. Int."},{"key":"B280","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3390\/pharmaceutics13040500","article-title":"PLGA nanoparticle-based formulations to cross the blood-brain barrier for drug delivery: from R&D to cGMP","volume":"13","author":"Zhi","year":"2021","journal-title":"Pharmaceutics"},{"key":"B281","doi-asserted-by":"publisher","first-page":"17656","DOI":"10.1039\/c8ra02424c","article-title":"Recent review of the effect of nanomaterials on stem cells","volume":"8","author":"Zhou","year":"","journal-title":"RSC Adv."},{"key":"B282","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jconrel.2017.12.015","article-title":"Crossing the blood-brain barrier with nanoparticles","volume":"270","author":"Zhou","year":"","journal-title":"J. Control Release"},{"key":"B283","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3389\/fneur.2020.00571","article-title":"Gender differences in non-sex linked disorders: insights from huntington's disease","volume":"11","author":"Zielonka","year":"2020","journal-title":"Front. Neurology"},{"key":"B284","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3389\/fphys.2014.00380","article-title":"Skeletal muscle pathology in huntington's disease","volume":"5","author":"Zielonka","year":"2014","journal-title":"Front. Physiol."},{"key":"B285","doi-asserted-by":"publisher","first-page":"197","DOI":"10.2174\/1570159X11311020006","article-title":"Cell-penetrating peptide-mediated therapeutic molecule delivery into the central nervous system","volume":"11","author":"Zou","year":"2013","journal-title":"Curr. Neuropharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1794983\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T05:40:52Z","timestamp":1778132452000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1794983\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":285,"alternative-id":["10.3389\/fphar.2026.1794983"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1794983","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"article-number":"1794983"}}